Table 1.
Patient characteristics.
| Total (n = 122) | ||
|---|---|---|
| Patient characteristics | Right-sided (n = 51) No. (%) | Left-sided (n = 71) No. (%) |
| Median age, years (range) | 68 (37–83) | 63 (34–82) |
| Gender | ||
| Male | 28 (54.9) | 42 (59.1) |
| Female | 23 (45.1) | 29 (40.9) |
| Performance Status (ECOG) | ||
| 0 | 43 (84.3) | 57 (80.3) |
| 1 + 2 | 8 (15.7) | 14 (19.7) |
| Stage at diagnosis | ||
| I–III | 8 (15.7) | 20 (28.2) |
| IV | 43 (84.3) | 51 (71.8) |
| Grading | ||
| 1 + 2 | 22 (48.9) | 43 (68.2) |
| 3 | 23 (51.1) | 20 (31.7) |
| Histological type | ||
| Adenocarcinoma NOS | 51 (100.0) | 68 (95.8) |
| Mucinous cancer | 0 | 3 (4.2) |
| CT regimen | ||
| FOLFOX4 | 31 (60.8) | 44 (62.0) |
| FOLFIRI | 20 (39.2) | 27 (38.0) |
| Prior cancer therapy | ||
| Surgery | 45 (88.2) | 50 (70.4) |
| Radiotherapy | 0 | 12 (16.9) |
| Adjuvant CT | 10 (19.6) | 8 (11.3) |
| Treatment group | ||
| CT + B | 26 (51.0) | 34 (47.9) |
| CT | 25 (49.0) | 37 (52.1) |
CT, chemotherapy; B, bevacizumab; NOS, not otherwise specified.